You are viewing the printer-friendly version of New Cartilage Restoring Surgery trying to enter US Markets

New Cartilage Restoring Surgery trying to enter US Markets

DeNovo^ŽET Living Cartilage Implant

DeNovo NT (Natural Tissue) is now in use. For the latest, read more.

DeNovo ET (Engineered Tissue) is still investigational, requiring FDA approval.

DeNovo ET, a scaffold-free, living cartilage implant, offers a one-step alternative to current cartilage repair. Designed to be offered as a product for the repair and regeneration of knee cartilage, DeNovo ET is applied to defects of the joint surface using a protein-based adhesive in a simple one-step procedure. DeNovo ET is hyaline cartilage, displaying biochemical properties similar to those of articular cartilage found in young, healthy joints (1). Because cells used to produce DeNovo ET are derived from juvenile tissue, DeNovo ET is expected to heal and regenerate damaged joint cartilage more effectively than technologies that use adult cells. Pre-clinical testing has demonstrated the ability of DeNovo ET to integrate with native cartilage and bone while retaining its hyaline properties (2). Read More...

A Phase I/II clinical trial for DeNovo ET is underway at three sites in the United States for the treatment of cartilage defects to restore joint function and to provide relief of knee pain. ISTO has partnered with Zimmer, Inc. to develop and commercialize Denovo ET.

Adkisson HD, IV, Gillis MP, Davis E C, et al. In vitro generation of scaffold independent neocartilage. Clin Orthop Rel Res 2001; 391S:S280-S294.
Lu Y, Adkisson HD, Bogdanske JP, et al. In vivo transplantation of neonatal ovine neocartilage allografts: determining the effectiveness of tissue transglutaminase. J Knee Surg 2005; 18:31-42.